Enrica Imbrogno

Via Piero Maroncelli, 40, FC
Meldola, 47014, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Correction to: Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Correction to: Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Journal: Cell biology and toxicology

Published: August 31, 2024

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Journal: Cell biology and toxicology

Published: April 14, 2021

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia.

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia.

Journal: Cancers

Published: September 02, 2019

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.

Journal: Journal of hematology & oncology

Published: April 30, 2018

RALE051: a novel established cell line of sporadic Burkitt lymphoma.

RALE051: a novel established cell line of sporadic Burkitt lymphoma.

Journal: Leukemia & lymphoma

Published: September 13, 2017

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.

Journal: Oncotarget

Published: February 12, 2016

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.

Journal: Journal of hematology & oncology

Published: July 09, 2015

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma.

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma.

Journal: Experimental hematology & oncology

Published: July 03, 2015

Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate.

Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate.

Journal: Oncogene

Published: November 18, 2014

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.

Journal: Oncotarget

Published: August 23, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026